title: [Intraarterial injection of low molecular weight dextran and urokinase for acute cerebral infarction].
abstract: Strategic recanalization of the occluded cerebral vessels has shown promise as a therapy for embolism and thrombosis in the acute stage. A single-dose of urokinase (UK) administered by intravenous and intraarterial routes was usually designed to restore patency of the infarct-related arteries and reperfuse the area of infarction. However, thrombolytic agents which have been available to date may lack resoluvability, limiting the amount of doses, because overdosage may induce hemorrhagic complication. This newly-designed therapy, intraarterial injection of UK-low molecular dextran (LMWD) complex was introduced in order to overcome the danger shown in the previous study. A high-resolvent allows cut-down of urkinase doses. Patients with acute cerebral infarction were selected for treatment with the resolvent if they satisfied the following conditions: 1) up to 79 years old without serious systemic diseases, 2) less than 12 hours from the onset, 3) better than the score of 8 in GCS, 4) no abnormality in CT scan, 5) apparent neurological deficit and 6) responsible pathology in angiography. LMWD of 15ml, UK of 240000IU and 15ml saline-complex was injected as one course at 2.0-2.5ml/min for 11 cases. Recanalization was observed in seven cases of embolism, and lack of reperfusion in five cases of thrombosis. The minimum effective dose was determined as 480000IU of UK in two courses. In terms of time lag from the onset, six hours may be the inferior limit, within which five of six cases (83%) succeeded in the recanalization.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurosurgery, Wakayama Red Cross Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Yabumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ryujin
authors.forename: S
authors.initials: S
authors.lastname: Imae
authors.forename: N
authors.initials: N
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Yukawa
authors.forename: I
authors.initials: I
authors.lastname: Kamei
authors.forename: M
authors.initials: M
authors.lastname: Iwamoto
authors.forename: T
authors.initials: T
authors.lastname: Kuriyama
mesh_terms: D000368:Aged; D002544:Cerebral Infarction / Q000188:drug therapy*; D003911:Dextrans / Q000008:administration & dosage* / Q000737:chemistry; D004359:Drug Therapy, Combination; D006801:Humans; D007269:Injections, Intra-Arterial; D008970:Molecular Weight; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D003911:Dextrans; D014568:Urokinase-Type Plasminogen Activator